Literature DB >> 27913835

Preventive DNA vaccination against CEA-expressing tumors with anti-idiotypic scFv6.C4 DNA in CEA-expressing transgenic mice.

Priscila M A Denapoli1, Bianca F Zanetti1, Adara A Dos Santos1, Jane Z de Moraes2, Sang W Han3,4.   

Abstract

Carcinoembryonic antigen (CEA) is expressed during embryonic life and in low level during adult life. Consequently, the CEA is recognized by the immune system as a self-antigen and thus CEA-expressing tumors are tolerated. Previously, we constructed a single chain variable fragment using the 6.C4 (scFv6.C4) hybridoma cell line, which gave rise to antibodies able to recognize CEA when C57/Bl6 mice were immunized. Here, the scFv6.C4 ability to prevent the CEA-expressing tumor growth was assessed in CEA-expressing transgenic mice CEA2682. CEA2682 mice immunized with the scFv6.C4 expressing plasmid vector (uP/PS-scFv6.C4) by electroporation gave rise to the CEA-specific AB3 antibody after the third immunization. Sera from immunized mice reacted with CEA-expressing human colorectal cell lines CO112, HCT-8, and LISP-1, as well as with murine melanoma B16F10 cells expressing CEA (B16F10-CEA). Cytotoxic T lymphocytes (CTL) from uP/PS-scFv6.C4 immunized mice lysed B16F10-CEA (56.7%) and B16F10 expressing scFv6.C4 (B16F10-scFv6.C4) (46.7%) cells, against CTL from uP-immunized mice (10%). After the last immunization, 5 × 105 B16F10-CEA cells were injected into the left flank. All mice immunized with the uP empty vector died within 40 days, but uP/PS-scFv6.C4 vaccinated mice (40%) remained free of tumor for more than 100 days. Splenocytes obtained from uP/PS-scFv6.C4 vaccinated mice showed higher T-cell proliferative activity than those from uP vaccinated mice. Collectively, DNA vaccination with the uP-PS/scFv6.C4 plasmid vector was able to give rise to specific humoral and cellular responses, which were sufficient to retard growth and/or eliminate the injected B16F10-CEA cells.

Entities:  

Keywords:  Anti-idiotypic antibody; Carcinoembryonic antigen; Colorectal cancer; DNA vaccine; Immunological tolerance; Single-chain fragment variable

Mesh:

Substances:

Year:  2016        PMID: 27913835     DOI: 10.1007/s00262-016-1940-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  4 in total

1.  scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.

Authors:  Bianca Ferrarini Zanetti; Camila Pontes Ferreira; José Ronnie Carvalho de Vasconcelos; Sang Won Han
Journal:  Gene Ther       Date:  2019-02-15       Impact factor: 5.250

2.  Adjuvant properties of IFN-γ and GM-CSF in the scFv6.C4 DNA vaccine against CEA-expressing tumors.

Authors:  Bianca Ferrarini Zanetti; Camila Pontes Ferreira; José Ronnie Carvalho Vasconcelos; Sang Won Han
Journal:  Gene Ther       Date:  2021-06-09       Impact factor: 5.250

3.  Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.

Authors:  Miao Wang; Fan Yang; Dana Huang; Yalan Huang; Xiaomin Zhang; Chao Wang; Shaohua Zhang; Renli Zhang
Journal:  Front Cell Infect Microbiol       Date:  2017-05-09       Impact factor: 5.293

4.  Prediction of occult tumor progression via platelet RNAs in a mouse melanoma model: a potential new platform for early detection of cancer.

Authors:  Yue Yin; Ruilan Jiang; Mingwang Shen; Zhaofang Li; Ni Yan; Junqiao Feng; Hong Jiang; Jiaxin Lv; Lijuan Shi; Lina Wang; Xi Liu; Kaiyun Zhang; Di Chen
Journal:  J Transl Med       Date:  2022-02-05       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.